SOURCE: Biolex Therapeutics

May 07, 2007 07:00 ET

Biolex Therapeutics Announces Agreement With Genmab for New Class of Antibodies

PITTSBORO, NC -- (MARKET WIRE) -- May 7, 2007 -- Biolex Therapeutics today announced an agreement with Genmab A/S, a leading antibody development company. Under the agreement Genmab will evaluate Biolex's patented LEX System(SM) as a potential manufacturing platform for antibodies developed with UniBody™, Genmab's proprietary new antibody technology.

"We are excited to be working with Genmab as their UniBody technology represents a major potential advancement in the antibody space and gives us the opportunity to further leverage our unique approach to protein production," said Jan Turek, President and CEO of Biolex. "We are pleased that Genmab, a company with world-class antibody expertise, recognizes the potential advantages of the LEX System approach to protein expression and antibody optimization."

About Biolex Therapeutics

Biolex Therapeutics is developing and commercializing therapeutic proteins based on the LEX System(SM), its patented expression system that enables the production of hard-to-make proteins and the optimization of monoclonal antibodies. The Company is developing a proprietary pipeline of products that rely upon known mechanisms of action to provide a reduced risk profile while targeting large, proven pharmaceutical markets. Biolex's lead clinical candidate, Locteron™, is being developed as a best-in-class controlled-release interferon alfa for the treatment of hepatitis C and is currently in Phase 2 testing. The Company's second product candidate, BLX-155, is a direct-acting thrombolytic, designed to break up clots in certain diseases such as acute peripheral arterial disease, deep vein thrombosis and catheter occlusion. In addition, the unique capabilities of the LEX System have led to collaborations with Centocor, Medarex and other leading pharmaceutical/biotech companies. Biolex is a venture capital-backed company located in the Research Triangle region of North Carolina, United States. For additional information, please visit Biolex's web site at www.biolex.com.

Contact Information

  • Contacts:

    Media:
    Michelle Linn
    Linnden Communications
    774-696-3803
    Email Contact.

    Investors:
    Dale Sander
    Chief Financial Officer
    858-663-6993
    Email Contact